Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2025-12-25 @ 11:34 PM
Study NCT ID:
NCT00262093
Status:
UNKNOWN
Last Update Posted:
2007-03-20
First Post:
2005-12-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Sponsor:
Hadassah Medical Organization
Organization:
Study Overview
Official Title:
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Status:
UNKNOWN
Status Verified Date:
2005-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.
Detailed Description:
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: